miReven scientists have been awarded a $530,000 NHMRC Development Grant to advance miR-7 as a novel cancer therapeutic.
Chief Investigators on the project Prof. Peter Leedman and Dr Christopher Wraight will apply the funding to the development of a series of novel miR-7 mimics with optimised drug-like properties. The project builds on the successful preclinical studies carried out by Prof. Leedman’s laboratory, and miReven Pty Ltd, a spin-out company from the University of Western Australia set up to commercialise the group’s miR-7 technology.